Stocks and Investing
Stocks and Investing
Thu, May 11, 2023
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
[ Thu, May 11th 2023
] - WOPRAI
Matthew Biegler Reiterated (ZNTL) at Buy and Held Target at $50 on, May 11th, 2023
Matthew Biegler of Oppenheimer, Reiterated "Zentalis Pharmaceuticals, Inc." (ZNTL) at Buy and Held Target at $50 on, May 11th, 2023.
Matthew, nor any peers, have made any analyst calls on ZNTL in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources